Health Care & Life Sciences » Pharmaceuticals | Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
22.50
26.60
34.50
43.40
45.70
-
Gross Income
22.50
26.60
34.50
43.40
45.70
-
SG&A Expense
10,289.20
14,564.90
20,363.90
18,636.80
18,633.90
35,757.20
EBIT
10,311.70
14,591.40
20,398.40
18,680.20
18,679.60
35,295.20
Unusual Expense
1,890.40
993.90
65.00
286.10
157.50
29.40
Non Operating Income/Expense
-
76.20
100.40
321.60
424.70
1,321.10
Pretax Income
12,154.60
15,509.10
20,233.00
18,072.50
18,412.40
34,003.50
Consolidated Net Income
12,154.60
15,509.10
20,233.00
18,072.50
18,412.40
34,003.50
Net Income
12,154.60
15,509.10
20,233.00
18,072.50
18,412.40
34,003.50
Net Income After Extraordinaries
12,154.60
15,509.10
20,233.00
18,072.50
18,412.40
34,003.50
Net Income Available to Common
12,154.60
15,509.10
20,233.00
18,072.50
18,412.40
34,003.50
EPS (Basic)
0.27
0.24
0.25
0.22
0.21
0.33
Basic Shares Outstanding
45,452.40
64,142.50
80,858.40
82,875.30
85,802.50
102,633.90
EPS (Diluted)
0.27
0.24
0.25
0.22
0.21
0.33
Diluted Shares Outstanding
45,452.40
64,142.50
80,858.40
82,875.30
85,802.50
102,633.90
EBITDA
10,289.20
14,564.90
20,363.90
18,636.80
18,634.00
35,257.20
Non-Operating Interest Income
47.40
-
-
-
-
-

About Catalyst Pharmaceuticals

View Profile
Address
355 Alhambra Circle
Coral Gables Florida 33134
United States
Employees -
Website http://www.catalystpharma.com
Updated 07/08/2019
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's disorder. The company was founded by McEnany J.